{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:14:04Z","timestamp":1790108044724,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.eplepsyres.2022.106897","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:29:10Z","timestamp":1646825350000},"page":"106897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients"],"prefix":"10.1016","volume":"182","author":[{"given":"Vaiva","family":"Petrenaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"\u00d6hman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Peter Thal","family":"Jantzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eplepsyres.2022.106897_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00498250902745082","article-title":"Variation in glucuronidation of lamotrigine in human liver microsomes.","volume":"May, 39","author":"Argikar","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.eplepsyres.2022.106897_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"28","author":"Beck","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00008571-200011000-00002","article-title":"Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance","volume":"10","author":"Bhasker","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.eplepsyres.2022.106897_bib4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"40","key":"10.1016\/j.eplepsyres.2022.106897_bib5","doi-asserted-by":"crossref","first-page":"10648","DOI":"10.1021\/bi00091a015","article-title":"Characterization of a cloned human dihydrotestosterone\/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms","volume":"32","author":"Chen","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.eplepsyres.2022.106897_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1528-1167.2007.00997.x","article-title":"Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial","volume":"48","author":"Christensen","year":"2007","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.106897_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1124\/jpet.104.067660","article-title":"UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver","volume":"310","author":"Court","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib8","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.12659\/MSM.897626","article-title":"Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children","volume":"22","author":"Du","year":"2016","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106897_bib9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/1055-9965.EPI-06-0823","article-title":"The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer","volume":"16","author":"Gallagher","year":"2007","journal-title":"Cancer Epidemiol., Biomark. Prev."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure - An impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","article-title":"Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy","volume":"57","author":"Gidal","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","article-title":"Pharmacogenomics of human UDP-glucuronosyltransferase enzymes","volume":"3","author":"Guillemette","year":"2003","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106897_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.05.016","article-title":"Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"155","author":"Johannessen Landmark","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bcpt.13120","article-title":"Meta-analysis of the influence of UGT genetic polymorphisms on lamotrigine concentration","volume":"124","author":"Kim","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib18","first-page":"1","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate","volume":"34","author":"Landmark","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4\u22173, UGT2B7\u2013161C\u2208>\u2208T and UGT2B7\u22172 on serum concentration of lamotrigine in Chinese epileptic children","volume":"71","author":"Liu","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy","volume":"34","author":"Lovric","year":"2012","journal-title":"Ther. Drug"},{"key":"10.1016\/j.eplepsyres.2022.106897_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","author":"Milosheska","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eplepsyres.2005.06.004","article-title":"Individual changes in lamotrigine plasma concentrations during pregnancy","volume":"65","author":"Petrenaite","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","article-title":"UGT polymorphisms and lamotrigine clearance during pregnancy","volume":"140","author":"Petrenaite","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(91)90012-5","article-title":"Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy","volume":"10","author":"Ramsay","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","article-title":"Frequencies of UGT1A4\u22172 (P24T) and\u22173 (L48V) and their effects on serum concentrations of lamotrigine","volume":"41","author":"Reimers","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine- valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eplepsyres.2016.09.004","article-title":"Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy","volume":"127","author":"Shen","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fendo.2013.00075","article-title":"Implication of human UGT2B7, 2B15, and 2B17 in 19-norandrosterone metabolism","volume":"4","author":"Strahm","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0000000000000577","article-title":"Relationship between UGT1A4 and UGT2B7 polymorphisms and the steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy","volume":"41","author":"Suzuki","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.dmpk.2014.12.007","article-title":"Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy","volume":"30","author":"Wang","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2022.106897_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107741","article-title":"Coffee and cigarette smoking interactions with lamotrigine","volume":"116","author":"Welty","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106897_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ygeno.2004.06.011","article-title":"Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15","volume":"84","author":"Wilson","year":"2004","journal-title":"Genomics"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:47:13Z","timestamp":1760276833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":33,"alternative-id":["S0920121122000481"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106897","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106897"}}